Dopamine agonists

Seminars in Neurology

Volumn 21, Issue 1, 2001, Pages 9-14

  Tuite, P ^a   Ebbitt, B ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Dopamine agonists; Parkinson's disease; Parkinson's disease treatment

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE; TOLCAPONE;

COST OF ILLNESS; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG USE; DYSKINESIA; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HUMAN; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO;

EID: 0035033026     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-13114     Document Type: Review

References (51)

1. Dopa and dopamine cause cultured neuronal death in the presence of iron
2. Induction of apoptosis in catecholaminergic PC 12 cells by L-dopa: Implications for the treatment of Parkinson's disease
3. Levodopa: Is toxicity a myth?
4. The role of dopamine agonists in early Parkinson's disease
5. Effects of repeated treatment with L-dopa, bromocriptine and ropinirole in drug-naive MPTP-treated common marmosets
6. Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys
7. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease
8. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease
9. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease
10. A six month study of pergolide and levodopa in de novo Parkinson's disease patients
11. Ropinirole for the treatment of early Parkinson's disease
12. A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease
13. Safety and efficacy of pramipexole in early Parkinson's disease: A randomized dose-ranging study
14. New alternatives for the management of early Parkinson's disease (PD)
15. A three and a half-year experience with pramipexole monotherapy in patients with early Parkinson's disease
16. Should treatment of Parkinson's disease be started with a dopamine agonist?
17. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
18. Tolcapone and fulminant hepatitis
19. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: An overview
20. Effect of ergot drugs on central catecholaminergic neurons: Evidence for stimulation of central dopamine neurons
21. Bromocriptine in parkinsonism
22. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism
23. Treatment of Parkinson's disease with bromocriptine
24. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease
25. Chronic agonist therapy for Parkinson's disease: A 5-year study of bromocriptine and pergolide
26. Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease
27. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
28. Pramipexole in patients with early Parkinson's disease
29. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
30. Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study
31. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease
32. Ropinirole for the treatment of early Parkinson disease: A 12-month experience
33. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease
34. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study
35. Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
36. Ropinirole in the symptomatic treatment of Parkinson's disease
37. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
38. Pleuropulmonary changes during long term bromocriptine treatment for Parkinson's disease
39. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide
40. Adverse effects of ergot-derivative dopamine agonists
41. Molecular biology of dopamine receptors
42. Dopamine receptor interactions: Some implications for the treatment of Parkinson's disease
43. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease
44. Failing asleep at the wheel: Motor vehicle m̊is̊haps in persons taking pramipexole and ropinirole
45. De l'apomorphine dans certains troubles nerveux
46. Apomorphine in Parkinson's disease
47. Treatment of Parkinson disease with apomorphines: Possible role of growth hormone
48. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease
49. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease
50. Dopaminergic agonists in the treatment of Parkinson's disease: A review